Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Receivables (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Change in Receivables for 14 consecutive years, with -$9.8 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 71.45% to -$9.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, down 54.8% year-over-year, with the annual reading at $5.8 million for FY2025, 54.8% down from the prior year.
  • Change in Receivables hit -$9.8 million in Q4 2025 for Corcept Therapeutics, down from $5.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $20.4 million in Q1 2024 to a low of -$9.8 million in Q4 2025.
  • Historically, Change in Receivables has averaged $1.7 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest YoY gain for Change in Receivables was 1259.67% in 2024; the steepest drop was 191925.0% in 2024.
  • Year by year, Change in Receivables stood at $1.1 million in 2021, then skyrocketed by 47.09% to $1.6 million in 2022, then skyrocketed by 295.44% to $6.5 million in 2023, then tumbled by 188.36% to -$5.7 million in 2024, then tumbled by 71.45% to -$9.8 million in 2025.
  • Business Quant data shows Change in Receivables for CORT at -$9.8 million in Q4 2025, $5.1 million in Q3 2025, and $2.7 million in Q2 2025.